Hypoxia and local tumour control in squamous cell carcinoma of the anus – a hypothesis-generating study

References

• Glynne-Jones R, Nilsson PJ, Aschele C, ESTRO, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol. 2014;111(3):330–339.
   PubMed Web of Science ®Google Scholar
• Bartelink H, Roelofsen F, Bosset JF, et al. 103 Radiotherapy with concomitant chemotherapy superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the EORTC radiotherapy and gastrointestinal tract cooperative groups. Int J Radiat Oncol. 1996;36(1):210.
   Google Scholar
• Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study. J Clin Oncol. 1996;14(9):2527–2539.
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Sebag-Montefiore D, Adams R, United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial Working Party, et al. Prognostic factors for recurrence and survival in anal cancer: Generating hypotheses from the mature outcomes of the first United Kingdom coordinating committee on cancer research anal cancer trial (ACT I). Cancer. 2013;119(4):748–755.
   PubMed Web of Science ®Google Scholar
• James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013;14(6):516–524.
   PubMed Web of Science ®Google Scholar
• Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86(1):27–33.
   PubMed Web of Science ®Google Scholar
• Northover JMA, Arnott SJ, Cunningham D, et al. Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996;348(9034):1049–1054.
   PubMed Web of Science ®Google Scholar
• Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR anal cancer trial (ACT I). Br J Cancer. 2010;102(7):1123–1128.
   PubMed Web of Science ®Google Scholar
• Peiffert D, Tournier-Rangeard L, Gérard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30(16):1941–1948.
   PubMed Web of Science ®Google Scholar
• Rao S, Sclafani F, Eng C, et al. InterAACT: a multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment. Ann Oncol. 2018;29(October):viii715–viii716.
   Google Scholar
• Guren MG, Aagnes B, Nygård M, et al. Rising incidence and improved survival of anal squamous cell carcinoma in Norway, 1987-2016. Clin Colorectal Cancer. 2019;18(1):e96–e103.
   PubMed Web of Science ®Google Scholar
• Shakir R, Adams R, Cooper R, et al. Patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2020;106(2):329–339.
   PubMed Web of Science ®Google Scholar
• Overgaard J, Horsman MR. Modification of Hypoxia-Induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol. 1996;6(1):10–21.
   PubMed Web of Science ®Google Scholar
• Bluemke E, Bulte D, Bertrand A, et al. Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma. Clin Transl Radiat Oncol. 2020;22:44–49.
   PubMed Web of Science ®Google Scholar
• Toustrup K, Sørensen BS, Metwally MAH, et al. Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials. Acta Oncol. 2016;55(9-10):1091–1098.
   PubMed Web of Science ®Google Scholar
• Toustrup K, Sørensen BS, Lassen P, Danish Head and Neck Cancer Group (DAHANCA), et al. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol. 2012;102(1):122–129.
   PubMed Web of Science ®Google Scholar
• Alsner J, Overgaard J, Tramm T, et al. Hypoxic gene expression is a prognostic factor for disease free survival in a cohort of locally advanced squamous cell cancer of the uterine cervix. Acta Oncol (Madr). 2021;0(0):1–7.
   PubMedGoogle Scholar
• Winther M, Alsner J, Tramm T, et al. Prognostic value of hypoxia-regulated gene expression in loco-regional gastroesophageal cancer. Acta Oncol. 2016;55(5):652–655.
   PubMed Web of Science ®Google Scholar
• Serup-Hansen E, Linnemann D, Skovrider-Ruminski W, et al. Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American joint committee on cancer stages I to III carcinoma of the anal canal. J Clin Oncol. 2014;32(17):1812–1817.
   PubMed Web of Science ®Google Scholar
• Toustrup K, Sørensen BS, Nordsmark M, et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res. 2011;71(17):5923–5931.
   PubMed Web of Science ®Google Scholar
• Danish Anal Cancer Group, clinical guidelines. doi:https://dacgnet.dk/kliniske-retningslinjer/.
   Google Scholar
• Saksø M, Mortensen LS, Primdahl H, et al. Influence of FAZA PET hypoxia and HPV-status for the outcome of head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy: Long-term results from the DAHANCA 24 trial (NCT01017224). Radiother Oncol. 2020;151:126–133.
   PubMed Web of Science ®Google Scholar
• Bentzen J, Toustrup K, Eriksen JG, et al. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. Acta Oncol. 2015;54(7):1001–1007.
   PubMed Web of Science ®Google Scholar